Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It seemed like they were running on all positive cylinders, but must have blown a gasket at current Conference/ Fireside???
Anybody follow CRBU??
Caribou Biosciences Inc 5.78 -1.44 (-19.94%)
Corp update seemed positive, so buy rumor, sell news?? Everything seems positive??
https://ih.advfn.com/stock-market/NASDAQ/caribou-biosciences-CRBU/stock-news/93466752/caribou-biosciences-reports-fourth-quarter-and-ful
Fireside chat at 11:20am (est.)…stay tuned
Foley pretty much confirmed the need for raise was
Related to ‘noise’ in the market regarding the credit facility…overhang is over, lol :) buy buy buy !!
Ditto! Picked up 5k @ $5.99 today…also sold naked puts( 5 strike/jul)…likely will sell naked Oct. 5strike
( ~ $1.25 per..only 5 O/I )
RVNC JUL 19 2024 $5 PUT
SO.9300 +S0.1300 (16.2500%)
Positions
Total value
-$4,000.00
Contracts owned
-40
Average cost
$1.06
Total gain/loss
+$252.88 (+5.94%)
Today's gain/loss
-$800.00 (-25.00%)
As of Mar-04-2024 4:43:14 p.m. ET
Purchase history
Acquired
- quantity
Average cost
Jan-11-2024
20
$1.03
Jan-24-2024
20
$1.09
Cool, gonna try and pick some off @ $6
True, and probably even if we had NOBO List, that wouldn’t be totally accurate as well( but closer)…I know it’s irrelevant, but that number stuck out , lol ..
I think Dew nailed it in a few posts that Foley underestimating, over ‘deliver’!
Nice!! Congrats!! Prob market maker(s) dropping bid to take a GTC sell limit order( small amount)
And/or it could be some of these reports that we’ll see over next couple days:
Needham Maintains Buy on Revance Therapeutics, Lowers Price Target to $18
Needham analyst Serge Belanger maintains Revance Therapeutics (RVNC.NaE) with a Buy and lowers the price target from $20 to $18.
Yep, saw that too!! Actually put order to buy @ $5.35 but missed it ( so far)…I peeked at the 10k and was looking for Fintech fail, Mgmt salaries and any Legal issues, and nothing really stood out..Will do a better Deep Dive later ..
Also, not that this is a market mover, but thought interesting ( and surprising in that at least 10% of these holders are on this Hub, lol)
Holders of Record
As of February 16, 2024, there were approximately 155 holders of record of our common stock, one of which was Cede & Co., a nominee for DTC. All of the shares of our common stock held by brokerage firms, banks and other financial institutions as nominees for beneficial owners are deposited into participant accounts at DTC and are therefore considered to be held of record by Cede & Co. as one stockholder.
10k is filed, could be some interesting nuggets:
http://archive.fast-edgar.com/20240228/AJZZG22CZ228U252222D22Z2EUKDZZ2S6P62
Maybe Just year end for tax harvesting ( if they can even benefit ) or YE portfolio shuffling….they were probably leaning it all the way down to $1.5 where I picked up a bunch ( sold some too early last week @ $3.55 ( can’t argue with taken a profit) …still my largest position and will hold until we get double digits ! Jesse was at those 2 conferences, plus the Bakers ( like you said, and totally agree) helps…
Data readouts coming soon ( prob by May)
OrbiMed filed 13g/a but can’t tell if they added or sold??
My buddy finally offering promo’s!
Pinsky Plastic Surgery • Following "•
Feb 5 •
And our February promotions are LIVE! This month at Pinsky Plastic Surgery take advantage of these limited time offers all month long!
Book Now & Save
$100 off Lip Filler
20% off Daxxify
New HydraFacial Glow Treatment $269
$499 Microneedling
New Sofwave Treatment
Don't wait! Secure your appointment today!
561-881-8800
pinskymd.com
FEBRUARY
PROMOTIONS
Home
SET THEIR HEARTS AFLUTTER WITH
Your Skin Aglow!
Try Daxxify!
Special offer 20% OFF regular pricing.
The newest neurotoxin to reduce frowning, fine lines and wrinkles.
Even Palm Beachers like deal$, lol
FYI: additional UK owner (amended )
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Revance Therapeutics, Inc.
(Name of Issuer)
December 31, 2023
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
x Rule 13d-1(b)
o Rule 13d-1(c)
o Rule 13d-1(d)
CUSIP No. 761330109
SCHEDULE 13G/A
Page 2 of 8 Pages
NAME OF REPORTING PERSONS
Polar Capital Holdings Plc
CITIZENSHIP OR PLACE OF ORGANIZATION
United Kingdom
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER
3,169,239
SHARED VOTING POWER
SOLE DISPOSITIVE POWER
3,169,239
SHARED DISPOSITIVE POWER
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,169,239
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
3.60%
12
TYPE OF REPORTING PERSON
HC
We talking about left Corner turns at Daytona?? lol :)…… ‘and this too will pass’ —-‘we’ve All been there, and done that’!! ‘This little piggy’ will rally! I’m ‘full of puns and fun’s’ today, Tito(s) was knocking at more door, someone’s ringing the bell….guess it’s our/ my first day of the year with cheer, hopefully Foley will shock the room!! Bahahaha:)
Maybe we get a bump from Conf’s:
Protara Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire 07:30AM ET, 01/31/2024
NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following investor conferences:
• Guggenheim Healthcare Talks 6th
Annual Biotechnology Conference. A fireside chat will take place on Wednesday, February 7, 2024 at
10:30 am ET in New York.
• Oppenheimer 34th Annual Healthcare Life Sciences Conference. A fireside chat will take place virtually on Wednesday, February 14, 2024 at
8:40 am ET.
Feb 2 (Reuters) - AbbVie Inc beat Wall Street estimates for fourth-quarter profit on Friday, helped by a smaller-than-expected decline in sales of its blockbuster drug, Humira, and strong demand for Botox amid stiff competition.
Botox brought in sales of $1.49 billion, ahead of combined estimates of $1.43 billion.
Botox has been facing increased competition from newer anti-wrinkle injections from Revance Therapeutics, Evolus and others.
Perhaps wishful thinking, but maybe we can learn some things that Mr. Market will appreciate??
Revance Therapeutics, Inc. (RVNC), today announced that the company will be participating in the Guggenheim Healthcare Talks, 6th Annual Biotechnology Conference, taking place February 7-8, 2024, in New York, New York. Chief Executive Officer, Mark J. Foley, is scheduled to participate in a fireside chat on Thursday, February 8, at 9:30a.m. EST.
However, most likely will be limited due to EPS later in month:
Next expected report date
Feb-26-2024
EPS growth
(Last qtr s same qtr prior year) - 39.32%
Yep, agreed ✔️
Looking forward hopefully to seeing some 13G/A’s, insider purchases, etc…Data readouts prob early Q2, maybe even late Q1 :)
Jesse keeps cash burn low, and RSU’s are reasonable to employees!!
Intrinsic value( after cash burn end of 2023) of perhaps $3.5-4per share( fully diluted share count about 18mm*)($50mm collecting interest income )
10k & Q prob out in March , should be good reading material
*series 1 preferred 8000sh can convert
FWIW,
Went naked J7.5 & 5’s!!!! Think the OnLy way to play it until Q2 at least…IV( implied voli is high ~96%)
If Exercised, avg. cost is closer to $15ish and will ONLY be down $1.2mm by then!!!! SMH !!!! Truth!!
$1.03 + 50.00 (-)
Implied volatility
Today's range
$1.03 x0
$1.00 x 492
$1.55 x 346
95.85%
Not that it matters at all, but just 1 acct.!!!! :
INDIVIDUAL - TOD
Details
Total value
$60,000.00
Shares owned
Average cost
10,000
$26.93
Total gain/loss Today's gain/loss
-S209,253.00 (-77.72%)
-$3, 100.00
AbbVie expects Botox to maintain market share as competition heats up
Reuters 2024-01-10T13:29:00-05:00
By Pratik Jain and Leroy Leo
Jan 10 (Reuters) - AbbVie (ABBV.NaE) expects Botox's market share in the aesthetics space to remain strong even as rivals launch competing anti-wrinkle injections, a company executive said on Wednesday.
Botox sales, especially for aesthetic use, have been under pressure over the last few quarters due to economic uncertainties. Investors have also been concerned about potential market share losses to new entrants such as Revance Therapeutics' (RVNC.NaE) Daxxify and Evolus' (EOLS.NaE)
Jeuveau.
Revance's Daxify has been of particular concern to
AbbVie's (ABBV.NaE) investors because its effects last about six months - nearly twice as long as Botox.
"We've been incredibly efficient at maintaining our leading share position of about 68%," AbbVie's (ABBV.NaE) Chief Commercial Officer Jeffrey Stewart said at the J.P. Morgan healthcare conference.
I like it, but when it goes thru that, $5’s & $6’s by end of Q1 after some readouts!!( look at 5yr chart)
Do we break $3 by e.o.m???
Just one man’s experience & hypothetical:
Although not face/ass( apples to apples), but back in 2016/17ish, I started to accumulate Exas( Cologuard I think just approved)..was buying from the mid teens, down to mid single digits…the company got Payers to pick up tab( I know, I ordered and pooped in the box, yes-TMI)..fortunately it picked up some polyps in the stool and got a colonoscopy shortly thereafter( several removed)…it was painful to accumulate, but paid off when Unfortunately sold covered calls to soon( $35-50 strikes)…it ended up going parabolic in 2020ish…What the Company did was go DTC and the ads( still active) created consumer demand and Health Care providers were besieged with requests…
So here’s the hypothetical: Once we get ‘J’ code, should Marketing dept go to the air with Ads/Dtc( realize this isn’t for aesthetics, but will help get name/benefits out( back door, no pun intended) …CD will be less TAM, but Cologuard should do $2.5b+ in sales from Zip 6yrs. Ago…
In summary, Kevin Conroy( ceo) made a great decision to go DTC, does Foley have the same agility?? Does it even make sense ??
Doesn’t really matter, I continue to accumulate Rvnc down here, and sell naked puts( jul 7.5 and open order for the $5’s @ $1 )
More M&A:
Jan 8 (Reuters) - Merck & Co said on Monday it would buy cancer drug developer Harpoon Therapeutics for about $680 million, reinforcing its oncology portfolio with immunotherapies.
The U.S. drugmaker has been doubling down on building future revenue streams as its blockbuster immunotherapy, Keytruda, inches closer to losing key patents, opening the doors for competition from biosimilars.
Merck has offered $23 per share in cash for California-based Harpoon, representing a 118% premium to the stock's last close on Friday.
Shares of Harpoon more than doubled premarket on Monday after deal talks were first reported by Bloomberg
And:
SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), today announced that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire all of the outstanding shares of Ambrx for $28.00 per share in cash, representing an approximately 105% premium to Ambrx’s closing stock price on January 5, 2024, for a total equity value of approximately $2.0 billion.
“We are excited to reach this agreement with Johnson & Johnson for advancing scientific research to treat cancers with high unmet needs,” said Daniel J. O’Connor, Chief Executive Officer of Ambrx. “With our deep and unique knowledge of precision engineering of protein therapeutics enabled by our proprietary technology incorporating synthetic amino acids in living cells, Ambrx has developed next-generation novel drug candidates such as site-specifically conjugated highly stable antibody drug conjugates. Through this transaction, we will continue to advance our leading prostate cancer candidate and Ambrx’s promising pipeline, while delivering significant and certain cash value to our shareholders. This announcement is the culmination of two decades of scientific work, combined with the Ambrx team’s talent, hard work and innovation. I look forward to what Ambrx will achieve as part of Johnson & Johnson.”
I don’t disagree, just was posting yet another bio raising capital over last several weeks and probably continue thru Q1 or so..Some of the raises’ are necessary and warranted, but others ( perhaps this one is an ATM machine) are for Salarie$….personally I Like to Measure the Decline in Mkt Cap(%) , relative to the dilution( $$) and then invest or not, depending on deviation I.E-10% discount or less I like it( tells me that the syndicate gave it to the institutions that will probably hold onto the shares for a while And buy more upon offering…
Bluebird was trading mid $3’s and offering was at a 50% discount ( needed funds in prob Q2/24, but rang cash register in q4(23’) and we still hemorrhaging)…in summary, regardless of Indication, BIO’s are raising big time in Q1 and opportunities ( or not) are plentiful..GLTA
Voyager Therapeutics Prices $100
Million Public Offering
MT Newswires 06:22AM ET, 01/05/2024
06:22 AM EST, 01/05/2024 (MT
Newswires) -- Voyager Therapeutics
(VYGR) said late Thursday it has priced an underwritten public offering of about 7.8 million common shares and pre-funded warrants to purchase about 3.3 million shares, at $9 per share and $8.999 for each pre-funded warrant.
Underwriters have been granted a 30-day option to buy up to about 1.7 million additional common shares.
Gross proceeds from the offering, which is expected to close around Jan. 9, are expected to be about $100 million.
The company said it plans to use the net proceeds from the offering, along with its existing cash and cash equivalents and marketable securities, to advance its anti-tau antibody program for the treatment of Alzheimer's disease and its SOD1 silencing gene therapy program for the treatment of amyotrophic lateral sclerosis into clinical development; to advance its tau silencing gene therapy program for the treatment of Alzheimer's disease, and its anti-amyloid gene therapy program for the treatment of Alzheimer's disease in preclinical development; to support its other preclinical development programs, and for working capital and other general corporate purposes.
I’m gonna stay out of this ‘love’ affair and just say that technically, ‘fundamentally’ and the fact that we have Whales in this ticker, $5 is realistic in 2024!! GLTA ( especially U2, lol) :)
Agreed!! Waiting to hear about upcoming Sales meeting and what was shared with team if possible…
Trying to be discreet as possible seeing PBeach is small community and I’m not sure who is/are reading these posts( see https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172076172…and the following 2 posts
I didn’t follow up because I’ve learned from youth that if you have nothing good to say, Zip it !!
So yes, Duration was an issue ( pricing to a lessor extent)… however, things have improved due to lowering the expectations(Education
And experience ) and the clientele are now preferring Daxxy over competition …not that anything we/ I post means much, but Emann and the other Med Spa / Aest owners have a better handle I presume …
Agreed, and whenever funds freed up, continue to accumulate from the $5’s handle to the $30’s!!
2024/25 ( if they remain independent) will be when I decide to exit or not…Top line growth , cash management and eventual B/E ( Profit almost secondary) will propel back into ~$5-6b EV( debt + 150mm OS by then most likely ‘imho’)…also, when
My bud who owns the largest Aesthetics operation in PBC(FL.) tells me that his Injectors have ceased / or to lessor extent, deter his clients from Daxxy , then bye bye !! But yes, some headwinds most likely!! GLTA
Here is full release:
Botox rival Revance loses bid to dismiss Allergan trade secrets lawsuit
Reuters 2024-01-04T11:47:00-05:00
By Mike Scarcella
Jan 4 (Reuters) - A federal judge on Wednesday said Botox maker AbbVie's (ABBV.NaE) Allergan unit can move ahead with its lawsuit accusing Revance Therapeutics (RVNC.NaE) of taking its confidential data to compete with Allergan's anti-wrinkle injections and facial fillers.
U.S. District Judge Eli Richardson in Nashville, Tennessee, ruled that Allergan plausibly alleged that Revance had acquired and used some of its rival's trade secrets amid a series of new hires from Allergan.
Richardson said Allergan had "presented enough circumstantial evidence" to overcome Revance's initial bid to dismiss the lawsuit, which was filed in April.
Nashville-based Revance obtained U.S. regulatory approval in 2022 for an anti-wrinkle injectable product it markets as Daxxify. Revance also separately is developing medication that is biologically similar to Allergan's Botox.
Attorneys for Revance and a representative for the company did not immediately respond to requests for comment on Thursday.
AbbVie (ABBV.NaE) also did not immediately respond to a request for comment.
AbbVie (ABBV.NaE) acquired Botox, which launched in 2002, through its $63 billion purchase of Allergan. The drug is also approved for chronic migraine headaches and other therapeutic uses, in addition to cosmetic purposes.
Global Botox net revenue for cosmetics was $620 million in the third quarter, and $748 million for therapeutics in the same period, AbbVie (ABBV.NaE) reported in October.
Allergan's lawsuit alleged Revance "accelerated" a plan to recruit from Allergan regulatory professionals, in-house lawyers and sales and marketing employees who were knowledgeable about Botox and the company's popular dermal filler Juvéderm.
The lawsuit said "it would be very challenging (if not impossible) to produce a biosimilar imitating Botox" without Allergan's confidential information.
Revance in seeking dismissal of the lawsuit said Allergan had not shown Revance had access to any of the trade secrets at issue and called the allegations "nonsensical." It said Allergan had "raced to the courthouse" after Revance won additional regulatory clearances to ramp up production of Daxxify.
Revance said in a court filing that Daxxify "represents a significant threat" to Botox.
The case is Allergan Inc v. Revance Therapeutics Inc (RVNC.NaE), U.S. District Court for the Middle District of Tennessee, No. 3:23-cv-00431.
For Allergan: Jennifer Baldocchi and Eric Dittmann of Paul Hastings; and William (Zan) Blue of Constangy, Brooks, Smith & Prophete
For Revance: Katie Molloy, James Boudreau and Gregory Bombard of Greenberg Traurig
Read more:
Allergan accuses Botox rival Revance of employee raiding in US lawsuit (Reporting by Mike Scarcella)
Ask, and you shall receive! Lol
Item 7.01
Regulation FD Disclosure.
bluebird bio, Inc. (the "Company") has signed a second outcomes-based agreement for LYFGENIA, bringing the cumulative total of covered lives for LYFGENIA to approximately 200 million, less than one month since FDA approval of LYFGENIA on December 8, 2023 for sickle cell disease in patients 12 and older with a history of vaso-occlusive events. Additional updates on the commercial launch of LYFGENIA will be presented at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024.
If anybody following Bluebird, and launch:
bluebird bio, Inc. (the "Company") has signed a second outcomes-based agreement for LYFGENIA, bringing the cumulative total of covered lives for LYFGENIA to approximately 200 million, less than one month since FDA approval of LYFGENIA on December 8, 2023 for sickle cell disease in patients 12 and older with a history of vaso-occlusive events. Additional updates on the commercial launch of LYFGENIA will be presented at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024.
Dang, you/we almost got what you asked for when an alert ( Form 4) just hit my email …but,
False alarm, Not open market purch!! Foley nor Sjuts:
Explanation of Responses:
These shares were acquired by Mr. Foley under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2023 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
1. These shares were acquired by Mr. Sjuts under the Issuer's 2014 Employee Stock Purchase Plan
Dew, having been a former MA. Resident until moving to Florida few years back, didn’t realize we had 1000+ Biotechs, wow!! This is kind of old news from last summer, but blows my mind how we went from an IT( Rte 128) to a leading Healthcare behemoth!!
https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1236234566_0.jpg?VersionId=dXQOXnGkR3pM1MhxBGE8yF7b_R.wYx3X
Bayer has opened a new cancer research and innovation center in Boston-Cambridge, Massachusetts, which is home to about—— 1,000 biotechs.—- (iStock / Getty Images Plus)
Bayer has opened a new U.S. cancer research and innovation center at the tune of $140 million—a move that will add 50 new jobs—as the German pharma attempts to become a top 10 oncology company by 2030.
The 62,100-square-foot precision molecular oncology research building is in biotech hub Kendall Square, a neighborhood of Boston-Cambridge, Massachusetts, which is home to about 1,000 biotechs.
And just recently, GS allocating sizable Capital to Life sciences:
Goldman Sachs is planning to make a splash in the life sciences sector, taking in $650 million for its first fund aimed at the drug development space.
I guess Point is 2024-30 Going to be an exciting space to be in!!! ( not just AI) :)
Ok, thanks UM…what day next week??